Briefing on MHRA routine inspection of non-commercial clinical trials

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
MHRA GCP Inspection 21st – 24th June 2011
Essential Documentation GCP Training Seminar 12th October 2011
Medicines and Healthcare products Regulatory Agency (MHRA) Statutory Good Clinical Practice (GCP) Inspection of Cardiff University.
Good Clinical Practice in Research Clinical Trial Regulations
Timelines Trust informed June 2007
Tips to a Successful Monitoring Visit
New Trials If you are seeking a collaboration with the UCL CCTU we require you to apply: At least 3 months before the application deadline By using the.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
The Early Phase (0-I-II) Clinical Drug Research Unit of Maastricht University Medical Center (MUMC) prof dr L. Van Bortel Drug Research Unit Maastricht.
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
Kenya AIDS Vaccine Initiative
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
Monitoring and Auditing
Practical Effective Steps to Improve Trial QUALITY from Audit/Inspections findings Cancer Clinical Trials Unit Scotland A NCRI Accredited Cancer Trials.
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Managing Sponsorship Research Services University of Oxford.
Learning from GMP Inspections. Richard Bateman QA Specialist Pharmacist East and South East England Specialist Pharmacy Services.
Notice of Compliance Audit
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
© Safeguarding public health Lynne Byers An Introduction to MHRA and GCP Inspections – Lynne Byers Medicines and Healthcare products Regulatory Agency.
Stanley Estime, MSCI December 9, 2014 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Ethics and Regulatory Approvals Alison Robertson CMDHB Research Officer.
Audits and Inspections in Clinical Research Jobin Kunjumon Vilapurathu.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
The work of the Research Ethics Committee Dr Carol Chu.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Breach reporting to the REC Catherine Blewett, HRA Improvement & Liaison Manager.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Quality & Regulatory Expectations of Outsourcing Oversight Nicky Dodsworth, VP Global Quality Assurance.
New from 2013… to 2017 Declaration of Helsinki 2013 Updated definition of Critical Audit Finding from HRA April 2014 European Regulation 2014 Care Act.
Safety Audits An essential tool for active safety management April 2015 Dr Emer Bell Integrated Risk Solutions.
Surviving CTIMPs and MHRA inspections Kim Gooding Diabetes and Vascular Medicine UEMS and Exeter CRF Exeter Clinical Research Facility.
A single approval for research in the NHS Wendy Fisher Research Applications Limited.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
GCP (GOOD CLINICAL PRACTISE)
Site Set-up and Conduct Caroline O’Leary and Carrie Bayliss.
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Briefing on MHRA routine inspection of non-commercial clinical trials
Remote Site Initiation Visits
Post MHRA Inspection What next?
Responsibilities of Sponsor, Investigator and Monitor
MAINTAINING THE INVESTIGATOR’S SITE FILE
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
CONDUCTING THE TRIAL AT
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Ray French Research Governance Manager, ACCORD.
Pharmacovigilance inspections: what HPRA expects
Good clinical practice
S A Overarching SOPs Funding Secured Training Records
Presentation transcript:

Briefing on MHRA routine inspection of non-commercial clinical trials Routine Good Clinical Practice (GCP) MHRA Inspection, University of Aberdeen 2011

Aims MHRA inspections MHRA inspection at University of Aberdeen How should staff prepare? Advice for staff on key areas of weakness So that: You can identify and address any actions required You can participate in the interviews with confidence University of Aberdeen can demonstrate that clinical trials are following current legislation and are conducted to high safety and quality standards.

Why do the MHRA Inspect? EU directive 2001/20/EC transposed into UK law May 2004 as Medicines for Human Use (Clinical Trials) Regulations 2004 Legal obligation to conduct Clinical Trials of Investigational Medical Products (CTIMPs) to Good Clinical Practice (GCP). MHRA is statutory body responsible for compliance with UK regulations MHRA inspect (CTIMPs) on humans covered by the regulations

3 Types of MHRA Inspection Routine Triggered Requested University of Aberdeen inspection is routine Provisionally 4 days week of 20 June 2011

Who do the MHRA inspect? Legally able to inspect all organisations ‘sponsoring’ or ‘hosting’ clinical trials in the UK Includes commercial and non-commercial organisations Adapt inspection to organisation type Routine inspections focus on systems

What do the MHRA inspect? University has systems in place to support conduct of CTIMPs in compliance with regulations (and GCP). Specific examples of CTIMPs to demonstrate those systems Areas of interest include: Approval processes and regulatory submissions Contract Management Trial file and data management Quality assurance and monitoring Training IT systems Pharmacovigilance Archiving Laboratories Pharmacy

What happens before the inspection? University notified by MHRA of inspection 4th February 2011 Dossier sent to MHRA on 4th March 2011. Including a list of CTIMPs (live and complete) to give an overview of clinical trial activity. MHRA provide draft agenda approx 6 weeks prior to the inspection Teleconference to finalise agenda approx 2 weeks prior to inspection University will coordinate the inspection

What are we doing to prepare? MHRA Inspection Internal Working Group Gap analysis and action plan Monitoring and Audit Informing staff of the inspection Staff training – GCP

What are the key areas of weakness? Qualifications and training Communication Delegation of duties Standard Operating Procedures Evidencing of information Study file and filing Pharmacovigilance Informed Consent Equipment Study closure and archiving

Pharmacovigilance Sponsor responsibility to ensure events are reported in accordance with regulations. Currently have central reporting (documented in CI delegation letter) . New SOP to be issued with updated process

Monitoring/Audit Sponsored studies will be audited to ensure that essential documents are present in the Trial Maser File. Training record will be required for trial personnel on a study delegation log.

What can you do to prepare? Handout available with recommendations for addressing key areas of weakness. SOPs for maintaining a Trial Master File, Investigator Site File, Pharmacovigilance will be available soon

What happens during the inspection? Opening meeting – inspectors present inspection plan Document review – including medical notes Interviews with selected staff Tour of facilities Additional requests Closing meeting – summary of findings and provisional grading

Interviews with study personnel on study conduct These assess knowledge of GCP and regulatory requirements, and probe for evidence of robust processes for ensuring compliance with GCP You should read through the example questions and answers provided.

Common Themes During Interview: Training Communication Safety reporting Protocol procedures & adherence Investigational medicinal product handling Informed consent Approval process including amendments Annual reports to ethics/MHRA Statistics and data handling Out of hours/leave cover Randomisation & un-blinding procedures End of trial & archiving procedures

Dos and Don’ts during Interview Be honest - we know we have some gaps and are addressing them - failure to recognize the gaps is more problematic than acknowledging the gaps Avoid being confrontational - esp. avoid giving the impression that this is ‘bureaucratic detail’ Be ‘alert’ to areas of improvement Avoid being defensive.

Dos and Don’ts during Interview Only answer the question asked If mistakes are made or wrong answers given, correct them at an appropriate time, or ensure somebody else does so. Try your best to correct any deficiencies noted by the inspectors before they leave Demonstrate confidence in your trial systems and data – you know it best. Be positive.

Dos and Don’ts during Interview Should inspection findings be made, make sure that you understand them completely – it is easier to ask the inspector for clarification during the inspection rather than after the report is issued. Don’t volunteer information It is appropriate to challenge a finding made by an inspector if you are certain they are incorrect, but do not persist in your objection.

What happens after the inspection? MHRA to report issues within 30 days of the inspection, summarising findings. University response will include an action plan, timelines to address any findings. MHRA receive response - will issue a closing letter and GCP Inspection Statement. Future inspections will be performed at a frequency determined by the MHRA. Possible routine GCP inspection of NHS Grampian

Summary Review your trial documentation and training files for staff. Have evidence of training (GCP certificate, CV) Ensure you can explain your role in the trial Review the typical questions and answers provided Familiarise yourself with new SOPs when available Be confident of your trial and processes. Remember that you know your trial better than anyone else.

Any Questions? Main Contacts: Prof Phil Hannaford – p.hannaford@abdn.ac.uk Prof Alison MacLeod – mmd175@abdn.ac.uk Dr Gail Holland – g.holland@abdn.ac.uk Tel: 01224 - 555076 Lynda Sime – lynda.sime@nhs.net Tel: 01224 -554656